MBX MBX Biosciences
- 20.360
- +0.090+0.44%
- 20.360
- 0.0000.00%
MBX Biosciences News
Earnings Scheduled For December 19, 2024
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...
Express News | Mbx Biosciences : Look Forward to Sharing Full-Topline Results of Mbx 1416 Program in Early January 2025
Express News | Mbx Biosciences Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences | 10-Q: Quarterly report
MBX Biosciences | 8-K: MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Mbx Biosciences: Strong Cash Position, With $277.1 Mln Expected to Support Operations Into Mid-2027
MBX Biosciences Reports Q3 EPS ($2.78), Consensus ($2.72)
MBX Biosciences 3Q Research and Development Expenses $16.7M >MBX
Earnings Flash (MBX) MBX BIOSCIENCES Posts Q3 Loss $-2.78 Per Share
Express News | Mbx Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Press Release: MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Bio Drops Despite Bullish Views on Street
MBX Biosciences Price Target Announced at $35.00/Share by Jefferies
Express News | Mbx Biosciences Shares Down 5.1%; Brokerages Initiate Coverage With Bullish Ratings
MBX Biosciences Earns Buy Rating at Three Investment Firms
No Data
